An engineered arginase FC protein inhibits tumor growth in vitro and in vivo

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Li, Lihua ^a   Wang, Yan ^b   Chen, Jun ^c,d   Cheng, Bi ^b   Hu, Jiehua ^e   Zhou, Yuehua ^f   Gao, Xin ^c   Gao, Liucun ^c   Mei, Xifan ^a   Sun, Meiyan ^g   Zhang, Zhuomei ^h   Song, Haifeng ^c  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PSYCHOLOGY   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e NAVAL UNIVERSITY OF ENGINEERING   (China)

^f Shanghai Junshi Biosciences Inc   (China)

^g THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^h General Hospital Chinese Armed Police   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HYBRID PROTEIN; RECOMBINANT ARGINASE FC FUSION PROTEIN; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84878739789     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/423129     Document Type: Article

References (33)

1. Varela M., Sala M., Llovet J. M., Bruix J., Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treatment Reviews 2003 29 2 99 104 2-s2.0-0037396639 10.1016/S0305-7372(02)00123-8 (Pubitemid 36519391)
2. Müller H. J., Boos J., Use of L-asparaginase in childhood ALL. Critical Reviews in Oncology/Hematology 1998 28 2 97 113 2-s2.0-0032145202 10.1016/S1040-8428(98)00015-8 (Pubitemid 28390409)
3. Wu G., Morris S. M., Arginine metabolism: nitric oxide and beyond. Biochemical Journal 1998 336 1 1 17 2-s2.0-0032533159 (Pubitemid 28532555)
4. Noh E. J., Kang S. W., Shin Y. J., Choi S. H., Kim C. G., Park I. S., Wheatley D. N., Min B. H., Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. International Journal of Cancer 2004 112 3 502 508 2-s2.0-6344291935 10.1002/ijc.20435 (Pubitemid 39390617)
5. Ensor C. M., Holtsberg F. W., Bomalaski J. S., Clark M. A., Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Research 2002 62 19 5443 5450 2-s2.0-0036792124
6. Kim R. H., Coates J. M., Bowles T. L., McNerney G. P., Sutcliffe J., Jung J. U., Gandour-Edwards R., Chuang F. Y. S., Bold R. J., Kung H. J., Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Research 2009 69 2 700 708 2-s2.0-58349098150 10.1158/0008-5472.CAN-08-3157
7. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., Cremona F., Ensor C. M., Holtsberg F. W., Bomalaski J. S., Clark M. A., Ng C., Curley S. A., Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. Journal of Clinical Oncology 2004 22 10 1815 1822 2-s2.0-3042744030 10.1200/JCO.2004.11. 120 (Pubitemid 41095171)
8. Lam T. L., Wong G. K. Y., Chong H. C., Cheng P. N. M., Choi S. C., Chow T. L., Kwok S. Y., Poon R. T. P., Wheatley D. N., Lo W. H., Leung Y. C., Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Letters 2009 277 1 91 100 2-s2.0-62249130842 10.1016/j.canlet.2008.11.031
9. van Rijn J., van Den Berg J., Schipper R. G., De Jong S., Cuijpers V., Verhofstad A. A. J., Teerlink T., Induction of hyperammonia in irradiated hepatoma cells: a recapitulation and possible explanation of the phenomenon. British Journal of Cancer 2004 91 1 150 152 2-s2.0-3342988480 10.1038/sj.bjc.6601915 (Pubitemid 39013059)
10. Storr J. M., Burton A. F., The effects of arginine deficiency on lymphoma cells. British Journal of Cancer 1974 30 1 50 59 2-s2.0-0016233602
11. Savoca K. V., Davis F. F., van Es T., Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the Taper liver tumor and the L5178Y murine leukemia. Cancer Biochemistry Biophysics 1984 7 3 261 268 2-s2.0-0021132808 (Pubitemid 14042662)
12. Cheng P. N. M., Lam T. L., Lam W. M., Tsui S. M., Cheng A. W. M., Lo W. H., Leung Y. C., Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Research 2007 67 1 309 317 2-s2.0-33846429217 10.1158/0008-5472.CAN-06-1945 (Pubitemid 46142789)
13. Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983 65 1-2 55 63 2-s2.0-0021061819 (Pubitemid 14203433)
14. Bussolino F., Camussi G., Baglioni C., Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor in interleukin 1 α Journal of Biological Chemistry 1988 263 24 11856 11861 2-s2.0-0023724630
15. Gong H., Zölzer F., Von Recklinghausen G., Rössler J., Breit S., Havers W., Fotsis T., Schweigerer L., Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochemical and Biophysical Research Communications 1999 261 1 10 14 2-s2.0-0345109251 10.1006/bbrc.1999.1004 (Pubitemid 29371610)
16. Beloussow K., Wang L., Wu J., Ann D., Shen W. C., Recombinant arginine deiminase as a potential anti-angiogenic agent. Cancer Letters 2002 183 2 155 162 2-s2.0-0037179556 10.1016/S0304-3835(01)00793-5 (Pubitemid 34628419)
17. Stordal B., Pavlakis N., Davey R., A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews 2007 33 8 688 703 2-s2.0-36049015023 10.1016/j.ctrv.2007.07. 013 (Pubitemid 350089290)
18. Graham M. L., Asselin B. L., Herndon J. E., Casey J. R., Chaffee S., Ciocci G. H., Daeschner C. W., Davis A. R., Gold S., Halperin E. C., Laughlin M. J., Martin P. L., Olson J. F., Kurtzberg J., Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplantation 1998 21 9 879 885 2-s2.0-0031953517 (Pubitemid 28200853)
19. Pui C. H., Evans W. E., Treatment of acute lymphoblastic leukemia. New England Journal of Medicine 2006 354 2 166 178 2-s2.0-30444437486 10.1056/NEJMra052603 (Pubitemid 43076714)
20. Scott L., Lamb J., Smith S., Wheatley D. N., Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. British Journal of Cancer 2000 83 6 800 810 2-s2.0-0033822017
21. Wheatley D. N., Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents. Anti-Cancer Drugs 2004 15 9 825 833 2-s2.0-8344258040 10.1097/00001813-200410000-00002 (Pubitemid 39482922)
22. Ascierto P. A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., Beneduce G., De Rosa V., Izzo F., Melucci M. T., Ensor C. M., Prestayko A. W., Holtsberg F. W., Bomalaski J. S., Clark M. A., Savaraj N., Feun L. G., Logan T. F., Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. Journal of Clinical Oncology 2005 23 30 7660 7668 2-s2.0-32944469353 10.1200/JCO.2005.02.0933 (Pubitemid 46291831)
23. Shen L. J., Lin W. C., Beloussow K., Shen W. C., Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Letters 2003 191 2 165 170 2-s2.0-0037430556 10.1016/S030-43835(02)00693-6 (Pubitemid 36255601)
24. Philip R., Campbell E., Wheatley D. N., Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. British Journal of Cancer 2003 88 4 613 623 2-s2.0-0037463235 10.1038/sj.bjc.6600681 (Pubitemid 36363373)
25. Wheatley D. N., Philip R., Campbell E., Arginine deprivation and tumour cell death: arginase and its inhibition. Molecular and Cellular Biochemistry 2003 244 1-2 177 185 2-s2.0-0037305059 10.1023/A:1022451705701 (Pubitemid 36411071)
26. Ni Y., Schwaneberg U., Sun Z. H., Arginine deiminase, a potential anti-tumor drug. Cancer Letters 2008 261 1 1 11 2-s2.0-39149099417 10.1016/j.canlet.2007.11.038
27. Way J. C., Lauder S., Brunkhorst B., Kong S. M., Qi A., Webster G., Campbell I., McKenzie S., Lan Y., Marelli B., Nguyen L. A., Degon S., Lo K. M., Gillies S. D., Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Engineering, Design and Selection 2005 18 3 111 118 2-s2.0-21044443734 10.1093/protein/gzi021 (Pubitemid 40638061)
28. Lo K. M., Sudo Y., Chen J., Li Y., Lan Y., Kong S. M., Chen L., An Q., Gillies S. D., High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Engineering 1998 11 6 495 500 2-s2.0-0031871573 (Pubitemid 28347259)
29. Albertella M. R., Green C. M., Lehmann A. R., O'Connor M. J., A role for polymerase η in the cellular tolerance to cisplatin-induced damage. Cancer Research 2005 65 21 9799 9806 2-s2.0-27544489816 10.1158/0008-5472.CAN-05-1095 (Pubitemid 41541457)
30. Morrison R. F., Seidel E. R., Vascular endothelial cell proliferation: regulation of cellular polyamines. Cardiovascular Research 1995 29 6 841 847 2-s2.0-0028998931 10.1016/0008-6363(96)88621-4
31. Shionoya S., Lu Y., Scanlon K. J., Properties of amino acid transport systems in K562 cells sensitive and resistant to cis- diamminedichloroplatinum(II). Cancer Research 1986 46 7 3445 3448 2-s2.0-0022641626 (Pubitemid 16096888)
32. Shen L. J., Lin W. C., Beloussow K., Hosoya K. I., Terasaki T., Ann D. K., Shen W. C., Recombinant arginine deiminase as a differential modulator of inducible (iNOS) and endothelial (eNOS) nitric oxide synthetase activity in cultured endothelial cells. Biochemical Pharmacology 2003 66 10 1945 1952 2-s2.0-0242266595 10.1016/S0006-2952(03)00555-0 (Pubitemid 37352857)
33. Reed E., Litterst C. L., Thill C. C., cis-Diamminedichloroplatinum(II-)- DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats. Cancer Research 1987 47 3 718 722 2-s2.0-0023110199 (Pubitemid 17027962)